FN1 and colorectal carcinoma: To further determine the potential clinical applications of these optimized J-I derivatives, we tested their activities on Fn, a common anaerobic gram-negative bacterium found in patients with intestinal microbiota dysbiosis, and their effects on the Fn-associated CRC.